Assertio Holdings is focused on advancing patient care through a diverse portfolio of FDA-approved products designed to address various medical conditions. The company currently offers eight products, including Cambia® (diclofenac potassium), INDOCIN® (indomethacin), Otrexup® (methotrexate), and ROLVEDON® (eflapegrastim-xnst), among others. Each product is accompanied by important safety information and prescribing details, ensuring that healthcare providers and patients are well-informed about their use. Assertio emphasizes the importance of safety and efficacy in its offerings, which are aimed at improving patient outcomes.

In addition to its product offerings, Assertio is committed to building strategic partnerships to enhance its portfolio and expand into new therapeutic areas. The company actively seeks late-stage and approved medications for in-licensing and acquisition, aiming to create mutually beneficial collaborations with other organizations. Assertio's partnership with Applied Pharma Research, which involves the licensing of drug delivery technology for Cambia, exemplifies its approach to innovation and life cycle management. Through these partnerships, Assertio strives to meet the needs of patients, healthcare providers, and payers, while optimizing returns for all parties involved.

United States

Assertio Holdings, Inc., a commercial pharmaceutical company, provides medicines in the areas of neurology, hospital, and pain and inflammation. The company’s pharmaceutical products include INDOCIN, an oral solution and a suppository form for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; moderate to severe ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides CAMBIA, a non-steroidal anti-inflammatory drug (NSAID) for the treatment of migraine, nausea, photophobia, and phonophobia; Zipsor, an NSAID for relief of mild to moderate acute pain; and SPRIX, an NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 1995 and is headquartered in Lake Forest, Illinois.

Central Nervous System (CNS)

Genetic Diseases

Immune System Diseases

Musculoskeletal Diseases

Pathological Conditions

Assertio Holdings

Rheumatoid arthritis

Indomethacin has analgesic, anti-inflammatory, and antipyretic properties.
The mechanism of action of INDOCIN, like that of other NSAIDs, is not &nbsp;completely understood but involves inhibition of cyclooxygenase (COX-1 &nbsp;and COX-2).
Indomethacin is a potent inhibitor of prostaglandin synthesis in &nbsp;vitro. Indomethacin concentrations reached during therapy have produced &nbsp;in vivo effects. Prostaglandins sensitize afferent nerves and potentiate &nbsp;the action of bradykinin in inducing pain in animal models. &nbsp;Prostaglandins are mediators of inflammation. Because indomethacin is an &nbsp;inhibitor of prostaglandin synthesis, its mode of action may be due to a &nbsp;decrease of prostaglandins in peripheral tissues.
<a href="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=06de3c9d-63bf-47c1-f78c-4fbdd482928a">Source</a>

INDOCIN Oral Suspension

Acute pain

Chronic pain

Pain

Oxycodone is a full opioid agonist and is relatively &nbsp;selective for the mu-opioid receptor, although it can bind to other &nbsp;opioid receptors at higher doses. The principal therapeutic action of &nbsp;oxycodone is analgesia. Like all full opioid agonists, there is no &nbsp;ceiling effect for analgesia with oxycodone. Clinically, dosage is &nbsp;titrated to provide adequate analgesia and may be limited by adverse &nbsp;reactions, including respiratory and CNS depression.
The precise mechanism of the analgesic action is unknown. However, &nbsp;specific CNS opioid receptors for endogenous compounds with opioid-like &nbsp;activity have been identified throughout the brain and spinal cord and &nbsp;are thought to play a role in the analgesic effects of this drug.
<a href="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cff0c64a-63f5-4b3c-909a-cdecf6755cbe">Source</a>

OXAYDO (oxycodone HCl, USP) tablets

Ketorolac has analgesic, anti-inflammatory, and antipyretic properties.
The mechanism of action of SPRIX, like that of other NSAIDs, is not &nbsp;completely understood but involves inhibition of cyclooxygenase (COX-1 &nbsp;and COX-2), an early component of the arachidonic acid cascade, &nbsp;resulting in the reduced synthesis of prostaglandins, thromboxanes, and &nbsp;prostacyclin.
Ketorolac is a potent inhibitor of prostaglandin synthesis in vitro. Ketorolac concentrations reached during therapy have produced in vivo effects. Prostaglandins sensitize afferent nerves and potentiate the &nbsp;action of bradykinin in inducing pain in animal models. Prostaglandins &nbsp;are mediators of inflammation. Because ketorolac is an inhibitor of &nbsp;prostaglandin synthesis, its mode of action may be due to a decrease of &nbsp;prostaglandins in peripheral tissues.
<a href="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=97005a1c-167e-4676-bae7-e49b38c36f9e">Source</a>

SPRIX (ketorolac tromethamine) Nasal Spray

Indomethacin has analgesic, anti-inflammatory, and antipyretic properties. 
 
The mechanism of action of INDOCIN, like that of other NSAIDs, is &nbsp;not completely understood but involves inhibition of cyclooxygenase &nbsp;(COX-1 and COX-2). 
 
Indomethacin is a potent inhibitor of prostaglandin synthesis in vitro. Indomethacin concentrations reached during therapy have produced in vivo effects. Prostaglandins sensitize afferent nerves and potentiate the &nbsp;action of bradykinin in inducing pain in animal models. Prostaglandins &nbsp;are mediators of inflammation. Because indomethacin is an inhibitor of &nbsp;prostaglandin synthesis, its mode of action may be due to a decrease of &nbsp;prostaglandins in peripheral tissues.
<a href="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e30a54dc-b62a-4ef7-9bea-daa8f5a685be">Source</a>

INDOCIN (indomethacin) Suppositories

Diclofenac has analgesic, anti-inflammatory, and antipyretic properties.
The mechanism of action of ZIPSOR, like that of other NSAIDs, is not completely
understood but involves inhibition of cyclooxygenase (COX-1 and COX-2).
Diclofenac is a potent inhibitor of prostaglandin synthesis in vitro. Diclofenac concentrations reached during therapy have produced in vivo effects. Prostaglandins sensitize afferent nerves and potentiate the action of bradykinin in inducing pain in animal models. Prostaglandins are mediators of inflammation. Because diclofenac is an inhibitor of prostaglandin synthesis, its mode of action may be due to a decrease of prostaglandins in peripheral tissues.
<a href="https://www.zipsor.com/pdf/prescribing-information.pdf">Source</a>

ZIPSOR (diclofenac potassium) Liquid filled capsules

Migraines

CAMBIA has analgesic, anti-inflammatory, and antipyretic properties.
The mechanism of action of CAMBIA, like that of other NSAIDs, is not completely understood but involves inhibition of cyclooxygenase (COX-1 and COX-2).
Diclofenac is a potent inhibitor of prostaglandin synthesis in vitro. Diclofenac concentrations reached during therapy have produced in vivo effects. Prostaglandins sensitize afferent nerves and potentiate the action of bradykinin in inducing pain in animal models. Prostaglandins are mediators of inflammation. Because diclofenac is an inhibitor of prostaglandin synthesis, its mode of action may be due to a decrease of prostaglandins in peripheral tissues.
<a href="http://www.cambiarx.com/prescribing-information">Source</a>

Assertio Holdings

Company Details